Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Sector

Healthcare

Industry

Biotechnology

CEO

Congleton, Jon

Employees

Website

mineralystx.com

IPO Date

2023-02-10

Headquarters

150 N. Radnor Chester Rd., Suite F200, Radnor, Pennsylvania, 19087, United States

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

Mineralys Therapeutics MLYS

Mineralys Therapeutics Earnings Call Summary

Mineralys Therapeutics Earnings

Transcripts

Events

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics
MLYS